Brief
GlobalData forecasts Alzheimer’s market to hit $14.7 bn by 2033
The forecast cites expensive disease‑modifying therapies, an aging population and new symptomatic drugs as growth drivers.
By Felo News Desk · Published
GlobalData said the Alzheimer’s disease (AD) market across the eight major markets (8MM) will expand from $2.4 billion in 2023 to $14.7 billion by 2033, a compound annual growth rate of 20 %.
What happened
The intelligence firm’s latest report, “Alzheimer’s Disease: Eight‑Market Drug Forecast and Market Analysis – Update (2026)”, projects that disease‑modifying therapies (DMTs) will account for 63.7 % of total sales in 2033, with amyloid‑beta‑targeting drugs forming the bulk of that share. The report also notes a rise in prevalent AD cases linked to an aging global population and the launch of new symptomatic therapies for agitation and psychosis.
What the reports add
According to GlobalData, Eli Lilly’s donanemab (Kisunla) and Eisai/Biogen’s lecanemab (Leqembi) are expected to become the top‑selling AD drugs, each generating roughly $2.9 billion and $2.8 billion in global sales by 2033. The firm highlights operational barriers such as intravenous administration and the need for PET or MRI scans, which could limit patient access. It also points to higher pricing compared with generic symptomatic treatments, creating reimbursement challenges in Japan and Europe.
What was said
Philippa Salter, Managing Neurology Analyst at GlobalData, said: “As the first DMTs to be approved in the 8MM, GlobalData forecasts that Eli Lilly’s Kisunla and Eisai/Biogen’s Leqembi will become the top‑selling drugs in the AD market and could generate global sales of approximately $2.9 billion and $2.8 billion, respectively, by 2033.” She added that “frequent IV administration and access to PET and MRI scans are key economic and operational barriers to patient access to these drugs.”
How it came about
The forecast builds on earlier GlobalData analyses of chronic‑disease markets, such as its recent dyslipidemia projection for 2035. The firm notes that developers are pursuing alternative delivery methods, including a subcutaneous autoinjector formulation of lecanemab (Leqembi Iqlik) that enables at‑home dosing in the United States. Late‑stage pipeline candidates with oral administration—AriBio’s AR1001, Annovis Bio’s buntanetap and Bristol Myers Squibb’s Cobenfy—are also highlighted as potential contributors to market growth if Phase III trials succeed.
Key facts
- GlobalData forecasts the 8MM Alzheimer’s drug market to reach $14.7 billion by 2033. (globaldata.com)
- Disease‑modifying therapies are projected to account for 63.7 % of total AD drug sales in 2033. (globaldata.com)
- Eli Lilly’s Kisunla and Eisai/Biogen’s Leqembi could each generate about $2.9 billion and $2.8 billion in sales by 2033. (globaldata.com)
- Barriers to DMT uptake include IV administration and the need for PET/MRI scans, as well as higher pricing and reimbursement issues. (globaldata.com)
- Oral late‑stage pipeline candidates such as AR1001, buntanetap and Cobenfy are identified as promising future contributors. (globaldata.com)
Sources
- [1] globaldata.com — originally reported as “Alzheimer’s disease market to reach $14. 7 billion in 8MM by 2033, forecasts GlobalData”
